Sugi Predict

Sugi Predict / Compounds / SCHEMBL1833943

SCHEMBL1833943

SCHEMBL1833943

CCCNOC(=O)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.55
▸ TDP1 Q9NUW8 4/20 0.54
▸ SLC6A3 Q01959 2/20 0.54
▸ HTR1A P08908 1/20 0.54
▸ CYP2D6 P10635 1/20 0.54
▸ SCN1A P35498 1/20 0.54
▸ SCN5A Q14524 1/20 0.54
▸ SCN2A Q99250 1/20 0.54
▸ SCN3A Q9NY46 1/20 0.54
▸ TSHR P16473 2/20 0.53
▸ KMT2A Q03164 4/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ MAPT P10636 2/20 0.52
▸ POLB P06746 1/20 0.52
▸ F2 P00734 1/20 0.47
▸ NAAA Q02083 1/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ RAB9A P51151 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3492807 0.89 LMNA (0.51) LMNATDP1SLC6A3HTR1ACYP2D6
SCHEMBL8519008 0.88 NAAA (0.57) LMNATDP1SLC6A3HTR1ACYP2D6
SCHEMBL11503257 0.86 NAAA (0.59) LMNATSHRKMT2AALDH1A1MAPT
SCHEMBL14981922 0.86 NAAA (0.59) LMNATSHRKMT2AALDH1A1MAPT
SCHEMBL14981917 0.86 NAAA (0.59) LMNATSHRKMT2AALDH1A1MAPT
SCHEMBL18196734 0.86 NAAA (0.59) LMNATSHRKMT2AALDH1A1MAPT
SCHEMBL16487021 0.85 NAAA (0.58) LMNATSHRKMT2AALDH1A1MAPT
SCHEMBL3492756 0.85 TSHR (0.57) LMNATDP1SLC6A3HTR1ACYP2D6
SCHEMBL10904247 0.83 KMT2A (0.53) LMNATDP1SLC6A3TSHRKMT2A
SCHEMBL27954014 0.83 ALDH1A1 (0.53) LMNATDP1SLC6A3HTR1ACYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10067131-B2 Fragment ligated inhibitors selective for the polo box domain of PLK1 UNIVERSITY OF SOUTH CAROLINA (US) 2018-09-04 — — US claimed
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES INC (US) 2024-01-25 — — US disclosed
US-11814376-B2 Hepatitis b core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2023-11-14 — — US disclosed
US-20230044112-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2023-02-09 — — US disclosed
US-10968211-B2 Hepatitis B core protein modulators ASSEMBLY BIOSCIENCES, INC. (US) 2021-04-06 — — US disclosed
EP-3782626-A1 HEPATITIS B CORE PROTEIN MODULATORS Assembly Biosciences, Inc. (US) 2021-02-24 — — EP disclosed
CN-112094264-A Hepatitis B core protein modulators 组装生物科学股份有限公司 2020-12-18 — — CN disclosed
CN-108347943-B Hepatitis B core protein modulators 组装生物科学股份有限公司 2020-07-10 — — CN disclosed
US-20200131168-A1 HEPATITIS B CORE PROTEIN MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2020-04-30 — — US disclosed
US-20180258084-A1 HEPATITIS B CORE PROTEIN MODULATORS ASSEMBLY BIOSCIENCES, INC. (US) 2018-09-13 — — US disclosed
CN-1713900-A Use of norepinephrine reuptake inhibitors for the treatment of cognitive disorders LILLY CO ELI (US) 2005-12-28 — — CN disclosed
CN-1146412-C Treatment of oppositional defiant disorder — 2004-04-21 — — CN disclosed
CN-1407890-A Treatment of psoriasis LILLY CO ELI (US) 2003-04-02 — — CN disclosed
CN-1271278-A Treatment of behavioral disorders LILLY CO ELI (US) 2000-10-25 — — CN disclosed
CN-1270520-A Treatment of oppositional defiant disorder LILLY CO ELI (US) 2000-10-18 — — CN disclosed
CN-1195287-A Treatment of attention-deficit and hyperactivity disorder LILLY CO ELI (US) 1998-10-07 — — CN disclosed
EP-0246825-A2 Quaternary salt solution electrolyte for electrolytic capacitors MITSUBISHI PETROCHEMICAL CO., LTD. (JP) 1987-11-25 — — EP disclosed
US-4157893-A MONO OR DISAZO DYE CONTAINING AN AMINO-SUBSTITUTED PYRIMIDINE RING BASF AKTIENGESELLSCHAFT (DE) 1979-06-12 — — US disclosed
US-4150943-A Uniformly dyed water-swellable cellulosic fibers BASF AKTIENGESELLSCHAFT (DE) 1979-04-24 — — US disclosed
US-4146535-A Azo dyes having a 3-cyano- or 3-carbamoyl-2,6-diamino-pyridine coupling component BASF AKTIENGESELLSCHAFT (DE) 1979-03-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10067131-B2 Fragment ligated inhibitors selective for the polo box domain of PLK1 PLK1, POLD1, CTDSP1 LMNA 2554/4885TDP1 525/4885SLC6A3 4630/4885
US-20240025890-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS LMNA 4706/4885TDP1 4337/4885SLC6A3 4731/4885
US-20230044112-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS LMNA 4706/4885TDP1 4337/4885SLC6A3 4731/4885
US-10968211-B2 Hepatitis B core protein modulators HAVCR2, FABP1, MAVS LMNA 4706/4885TDP1 4337/4885SLC6A3 4731/4885
US-11814376-B2 Hepatitis b core protein modulators HAVCR2, FABP1, MAVS LMNA 4706/4885TDP1 4337/4885SLC6A3 4731/4885
US-20200131168-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS LMNA 4706/4885TDP1 4337/4885SLC6A3 4731/4885
US-20180258084-A1 HEPATITIS B CORE PROTEIN MODULATORS HAVCR2, FABP1, MAVS LMNA 4706/4885TDP1 4337/4885SLC6A3 4731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.